Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197 is registered in ClinicalTrials.gov with Ascenta Therapeutics as lead sponsor.

NCT NCT00561197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00561197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
Lead sponsor
Ascenta Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2007
Completion date
September 30, 2010
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced esophageal or ge junction cancer